Skip to main content
. 2016 May 13;7(25):37846–37856. doi: 10.18632/oncotarget.9344

Figure 1. Immunohistochemical expression of HELLS (A, B), ZIC2 (C, D) and ZIC5 (E, F) in prostate cancer.

Figure 1

HELLS is positive in a small subpopulation of tumor cells (arrowheads). ZIC2 is negative (C) or moderately positive in a high percentage of cells with both cytoplasmatic and nuclear expression (D). ZIC5 shows sporadic (E) or moderate (F) nuclear expression in scattered cells. Original magnifications, 400×.